Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
5.11
+0.05 (0.99%)
At close: Mar 9, 2026, 4:00 PM EDT
5.09
-0.02 (-0.39%)
After-hours: Mar 9, 2026, 6:56 PM EDT
Niagen Bioscience Revenue
In the year 2025, Niagen Bioscience had annual revenue of $129.42M with 29.95% growth. Niagen Bioscience had revenue of $33.84M in the quarter ending December 31, 2025, with 16.19% growth.
Revenue (ttm)
$129.42M
Revenue Growth
+29.95%
P/S Ratio
3.17
Revenue / Employee
$1,244,452
Employees
104
Market Cap
410.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 129.42M | 29.83M | 29.95% |
| Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
| Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
| Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
| Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 30, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 105.65M |
| Enanta Pharmaceuticals | 66.98M |
| Autolus Therapeutics | 51.13M |
| Crescent Biopharma | 10.84M |
| PureTech Health | 6.39M |
| Immutep | 5.28M |
| Upstream Bio | 2.80M |
NAGE News
- 4 days ago - Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 - Business Wire
- 11 days ago - Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction - Business Wire
- 12 days ago - Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen® - Business Wire
- 4 weeks ago - Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen - Business Wire
- 4 weeks ago - Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 - Business Wire
- 7 weeks ago - Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.* - Business Wire
- 2 months ago - Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast - Business Wire